NKTR Short Volume

Nektar Therapeutics (NKTR) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $1.24B, listed on NASDAQ, employing roughly 61 people, carrying a beta of 1.15 to the broader market. Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Led by Howard W. Robin, public since 1994-05-03.

Short volume measures the number of shares sold short on a given day as reported by FINRA. Tracking short volume relative to total volume helps identify unusual bearish sentiment or short-squeeze potential.

Latest Date

2026-06-30

Short Volume

364.1K

Total Volume

533.7K

Short %

68.21%

30-Day Avg Short %

54.62%

Showing 30 days of FINRA short volume data for Nektar Therapeutics.

Learn how short volume is reported and how to read the data →

Frequently asked NKTR short volume questions

What is the daily NKTR short volume?

As of Jun 30, 2026, Nektar Therapeutics (NKTR) short volume is 364.1K shares against 533.7K total reported volume, or 68.21% short-side. Short volume measures shares sold short during the day; it is flow, not inventory.

How is NKTR short volume reported?

FINRA publishes the Daily Short Sale Volume File for trades reported to FINRA TRFs and the FINRA/Nasdaq ADF on a T+1 basis. The headline figure is the count of shares that printed at the short-sale or short-exempt tick across all reporting venues for the symbol; each exchange separately publishes its own daily short-sale data file.

What does NKTR short volume tell options traders?

Daily short-sale flow is one input that helps disambiguate dealer-hedging activity from directional bear flow when the chain shows fresh customer call inventory. It is not a clean MM-only proxy: the headline number mixes directional shorting, options-MM delta-hedging, ETF-creation arbitrage, and convertible-arb hedging. Cross-check against gamma-exposure and OI changes for a cleaner read.